After landing the all-important validation of a deal with GlaxoSmithKline Biologicals in December, GlycoVaxyn AG is expecting to finalize an agreement to fund development of its lead in-house program and seal further collaborations around its conjugated vaccine technology platform in 2013.
Read More
More than 40 years after it was first proposed, a single European patent will come into effect on Jan. 1, 2014, after a compromise deal was endorsed last month.
Read More
A candidate drug that has previously been evaluated as a treatment for stroke turns out to be able to kill some types of pathogenic bacteria, an international team of researchers has found.
Read More
In the six decades since Watson and Crick discovered the structure of DNA, rarely has a year passed in the biopharmaceutical sector which could be defined as boring.
Read More
